Literature DB >> 7977998

Pancreaticoduodenectomy for suspected but unproven malignancy.

J S Thompson1, K M Murayama, J A Edney, L F Rikkers.   

Abstract

BACKGROUND: Pancreaticoduodenectomy is an accepted surgical option for certain benign conditions and biopsy proven cancer. Whether this procedure should be performed when malignancy of the pancreas and periampullary region is suspected but not confirmed represents a fairly common intraoperative dilemma. PATIENTS AND METHODS: Sixty-seven patients who had undergone pancreaticoduodenectomy during a 15-year period were evaluated retrospectively.
RESULTS: The indications for resection were symptomatic benign conditions (n = 10, 15%), proven pancreatic or periampullary cancer (n = 37, 55%), and suspected but unproven malignancy (n = 20, 30%). The patients with suspected malignancy ranged in age from 27 to 73 years. Common findings in this group were abdominal pain (75%), jaundice (70%), weight loss (65%), and alcohol use (45%). There were 14 pancreatic and 6 ampullary masses. Biopsies obtained preoperatively (n = 15) and intraoperatively (n = 11) were nonconfirmatory. Postoperatively 9 patients (45%) were found to have tumors, including 6 pancreatic adenocarcinoma, 2 duodenal adenocarcinoma, and 1 islet cell tumor. Six of the 8 adenocarcinomas (75%) were stage I. Seven patients were alive 11 to 108 months later. The most common benign diagnosis was pancreatitis. There were 8 complications and 1 death.
CONCLUSIONS: Pancreaticoduodenectomy performed based on suspicion alone frequently reveals malignancy. Immediate and long-term outcomes are acceptable. These findings justify a continued aggressive approach to suspected pancreatic and periampullary malignancy.

Entities:  

Mesh:

Year:  1994        PMID: 7977998     DOI: 10.1016/s0002-9610(05)80124-2

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  13 in total

1.  Update of PET and PET/CT for hepatobiliary and pancreatic malignancies.

Authors:  Dominique Delbeke; William H Martin
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

2.  Evaluation of pCLE in the bile duct: final results of EMID study : pCLE: impact in the management of bile duct strictures.

Authors:  Fabrice Caillol; Erwan Bories; Aurelie Autret; Flora Poizat; Christian Pesenti; Jacques Ewald; Olivier Turrini; Jean Robert Delpero; Genevieve Monges; Marc Giovannini
Journal:  Surg Endosc       Date:  2014-12-10       Impact factor: 4.584

3.  The role of 18F-fluorodeoxyglucose positron emission tomography in the management of patients with pancreatic adenocarcinoma.

Authors:  Lujaien A Kadhim; Avani S Dholakia; Joseph M Herman; Richard L Wahl; Muhammad A Chaudhry
Journal:  J Radiat Oncol       Date:  2013-10-30

4.  Benign disease and unexpected histological findings after pancreaticoduodenectomy: the role of endoscopic ultrasound fine needle aspiration.

Authors:  Tommaso Maria Manzia; Luca Toti; Ilaria Lenci; Magdy Attia; Laura Tariciotti; Simon R Bramhall; John A C Buckels; Darius F Mirza
Journal:  Ann R Coll Surg Engl       Date:  2010-05       Impact factor: 1.891

Review 5.  The Impact of Recent Advances in Endoscopic Ultrasound-Guided Tissue Acquisition on the Management of Pancreatic Cancer.

Authors:  Susana Marques; Miguel Bispo; Ricardo Rio-Tinto; Paulo Fidalgo; Jacques Devière
Journal:  GE Port J Gastroenterol       Date:  2020-10-23

Review 6.  18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer.

Authors:  D M Rose; D Delbeke; R D Beauchamp; W C Chapman; M P Sandler; K W Sharp; W O Richards; J K Wright; M E Frexes; C W Pinson; S D Leach
Journal:  Ann Surg       Date:  1999-05       Impact factor: 12.969

7.  Surgically proved visually isoattenuating pancreatic adenocarcinoma undetected in both dynamic CT and MRI. Was blind pancreaticoduodenectomy justified?

Authors:  Konstantinos Blouhos; Konstantinos A Boulas; Dimitrios G Tselios; Stavroula P Katsaouni; Basiliki Mauroeidi; Anestis Hatzigeorgiadis
Journal:  Int J Surg Case Rep       Date:  2013-02-24

8.  Unexpected benign histopathology after pancreatoduodenectomy for presumed malignancy: accepting the inevitable.

Authors:  Rachel M Gomes; Munita Bal; Shraddha Patkar; Mahesh Goel; Shailesh V Shrikhande
Journal:  Langenbecks Arch Surg       Date:  2016-01-26       Impact factor: 3.445

9.  Incidence and characteristics of chronic and lymphoplasmacytic sclerosing pancreatitis in patients scheduled to undergo a pancreatoduodenectomy.

Authors:  Steve M M de Castro; Lindsey C F de Nes; C Yung Nio; Daan C Velseboer; Fiebo J W ten Kate; Olivier R C Busch; Thomas M van Gulik; Dirk Jan Gouma
Journal:  HPB (Oxford)       Date:  2010-02       Impact factor: 3.647

10.  Results of pancreaticoduodenectomy for lymphoplasmacytic sclerosing pancreatitis.

Authors:  Jeffrey M Hardacre; Christine A Iacobuzio-Donahue; Taylor A Sohn; Susan C Abraham; Charles J Yeo; Keith D Lillemoe; Michael A Choti; Kurtis A Campbell; Richard D Schulick; Ralph H Hruban; John L Cameron; Steven D Leach
Journal:  Ann Surg       Date:  2003-06       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.